Business Context and Reporting Period
This Form 8-K Current Report was filed by Ultragenyx Pharmaceutical Inc. on March 14, 2023. The filing addresses Item 5.02 regarding the departure of certain officers and the appointment of new officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and role transitions.
Material Changes
- Executive Transition: Camille L. Bedrosian, M.D., is transitioning from Executive Vice President and Chief Medical Officer to Strategic Development Advisor, effective May 1, 2023.
- Appointment: Eric Crombez, M.D., currently Chief Medical Officer for Gene Therapy and Inborn Errors of Metabolism, will assume the role of Executive Vice President and Chief Medical Officer effective May 1, 2023.
- Compensation Adjustment: Dr. Bedrosian's base salary will decrease from $600,000 to $500,000. Her target bonus will decrease from 50% to 35% of base salary.
- Equity Awards: Dr. Bedrosian is expected to receive a target 2023 equity award of 6,900 restricted stock units and 9,200 stock options.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. It details severance contingencies for Dr. Bedrosian, noting that if terminated without Cause or resigning due to Constructive Termination on or before May 1, 2024, severance benefits will be calculated based on her current base salary of $600,000 and 50% target bonus. Terminations occurring after May 1, 2024, would be based on the salary and bonus amounts in effect at that time.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (May 1, 2023).
- Verify the specific terms of the amended Offer Letter regarding Dr. Bedrosian's new compensation package.
- Review the definitions of "Cause" and "Constructive Termination" in the original Offer Letter to understand severance triggers.
- Monitor future filings for the formal execution of the amended Offer Letter.